Innovita Biological Technology Co. Ltd. A

688253 · SHG · Healthcare / Biotechnology

47.75CNY-1.72 (-3.48%)

Price History

Full chart

Market Stats

Previous Close49.47

Open49.50

Day Range47.50 – 50.02

52-Week Range29.77 – 73.58

Volume652.42K

Market Cap7.49B

P/E (TTM)146.81

Forward P/E0.00

EPS0.37

Dividend Yield0.83%

Beta1.10

50-Day Avg57.71

200-Day Avg47.81

About

Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in research and development, production and sales of POCT rapid diagnostic products. It offers Covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test and TORCH test, neurological testing and hepatitis test, as well as tropical disease test such as neurological testing. The company was founded in 2006 and is based in Beijing, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMs. Xiujie Zhang
Employees474
Headquarters1st and 2nd floors, Beijing, China, 100070, China
Websitehttps://www.innovita.com.cn

Leadership

Ms. Xiujie ZhangGM & Director · b. 1971
Ms. Xiujuan ZhaoFinancial Director & Director · b. 1974
Mr. Xiaogang ZhangDeputy GM & Director · b. 1964
Mr. Fukang ChenBoard Secretary · b. 1984
Yingsheng ZhaoAccounting Supervisor

Financials

Income Statement

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.04B	326.91M	446.62M	478.02M	621.39M	422.03M
Growth (%)	-	-68.48%	+36.62%	+7.03%	+29.99%	-32.08%
Cost of Revenue	110.50M	76.28M	173.28M	114.81M	123.51M	91.68M
Gross Profit	926.60M	250.63M	273.34M	363.21M	497.88M	330.35M
Gross Margin	89.35%	76.67%	61.20%	75.98%	80.12%	78.28%
Operating Expense	215.75M	104.73M	154.34M	147.44M	248.95M	201.46M
Operating Income	710.86M	145.90M	119.00M	215.77M	248.93M	128.89M
Operating Margin	68.54%	44.63%	26.64%	45.14%	40.06%	30.54%
EBITDA	-	-	183.97M	224.02M	298.42M	186.43M
EBITDA Margin	-	-	41.19%	46.87%	48.02%	44.17%
Net Income	571.45M	120.25M	150.68M	173.95M	246.86M	144.47M
Net Income Margin	55.10%	36.78%	33.74%	36.39%	39.73%	34.23%
R&D	59.41M	31.11M	72.18M	53.11M	97.17M	94.91M
R&D as % of Total Revenue	5.73%	9.52%	16.16%	11.11%	15.64%	22.49%
Interest Expense	175.63K	133.88K	409.45K	199.59K	114.56K	156.05K
Interest Expense % of Total Revenue	0.02%	0.04%	0.09%	0.04%	0.02%	0.04%

Balance Sheet

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	782.09M	797.87M	1.94B	2.07B	2.21B	2.28B
Total Liabilities	114.08M	59.70M	253.24M	223.65M	219.07M	223.32M
Total Equity	667.65M	738.17M	1.69B	1.84B	1.99B	2.05B
Cash	482.05M	479.74M	388.67M	166.46M	307.73M	567.09M

Cash Flow

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	639.82M	106.27M	126.43M	259.85M	305.46M	193.13M
Capital Expenditure	76.71M	63.75M	57.71M	16.97M	36.16M	31.13M
Free Cash Flow	563.10M	42.52M	68.71M	242.89M	269.31M	162.00M
Dividends Paid	100.29M	50.07M	217.38K	22.64M	54.42M	75.23M
FCF to OCF	88.01%	40.01%	54.35%	93.47%	88.16%	83.88%
Dividend Paid to FCF	17.81%	117.74%	0.32%	9.32%	20.21%	46.44%

Earnings

Report Date	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
EPS Estimate	-	-	-
EPS Actual	0.14	0.17	0.40
Surprise	-	-	-
Timing	-	-	-

Key Statistics & Ratios

Market Cap7.49B

Enterprise Value6.16B

Trailing P/E146.81

Forward P/E0.00

Price / Sales26.17

Price / Book3.90

EPS0.37

Book Value15.04

Revenue (TTM)286.33M

Gross Profit (TTM)205.63M

EBITDA50.77M

Profit Margin17.64%

Operating Margin-66.71%

Return on Equity2.50%

Return on Assets0.79%

Shares Outstanding137.97M

Shares Float117.40M

Beta1.10

Dividend Yield0.83%

Dividend Rate0.45

Payout Ratio121.62%

Dividends

20261×

0.45Jun 16, 2026

20251×

0.56Jun 24, 2025

20241×

0.40Jun 6, 2024

20231×

0.17May 19, 2023